[Cerebral ischemic vasculopathy: clinical and thermographic study in patients treated with papaveroline].

F. Nico,F. Guercini,A. Biagi,S. Fanfoni

1981-07-31

Abstract:

What problem does this paper attempt to address?

The Predictive Role of MTHFR and ABCG2 Single Nucleotide Polymorphisms on the Outcome of Advanced Colorectal Cancer Treated with First-Line Chemotherapy

J. Zhao,W. Zhang,W. Li,J. Li,W. Guo,S. Cai,M. Sun,Z. Zhang,D. Zhu,Q. Yu

DOI: https://doi.org/10.1016/s0923-7534(20)33112-4

IF: 51.769

2012-01-01

Annals of Oncology

Abstract:ABSTRACT Objective Chemotherapy with 5-fluorouracil and oxaliplatin (FOLFOX or XELOX) or irinotecan (FOLFIRI) has become the mainstay of treatment for advanced colorectal cancer. Since not all patients would benefit from the chemotherapy they received, exploring factors that would predict better effectiveness remains meaningful for understanding the concept of individual treatment. The purpose of this study is to confirm the predictive role of a serial of SNPs, MTHFR C677T, A1298C, ABCG2 G34A and C421A, as well as the clinical features for the efficacy of first-line chemotherapy in advanced colorectal cancer. Methods Patients with advanced colorectal cancer and treated with first-line standard FOLFOX/XELOX or FOLFIRI regimens between January 2009 and May 2011 at Fudan University Shanghai Cancer Center were retrospectively studied. Gene polymorphisms of MTHFR and ABCG2 were detected using gene sequencing method, after DNA extraction from peripheral blood karyocytes and PCR amplification. Results Of all 154 patients, patients with 3 ∼ 4 of the favorable genotypes (MTHFR 677C/C, MTHFR 1298 A/A, ABCG2 G/A or A/A， and ABCG2 421C/A or A/A) had a longer PFS than those with 0 ∼ 2 above genotypes (9.8m vs. 7.5m, P = 0.013; HR = 0.627, 95%CI: 0.427 ∼ 0.920, P = 0.017) The radical resection of primary lesion was also found as an independent factor for both PFS (HR = 0.524, 95%CI: 0.320 ∼ 0.859, P = 0.010) and OS (HR = 0.291, 95%CI: 0.147 ∼ 0.575, P = 0.000). Interestingly, stratified univariate analysis revealed that patients with 2 ∼ 4 genotypes of MTHFR 677C/C、MTHFR 1298 A/C or C/C、ABCG2 34G/G and ABCG2 421C/A or A/A would benefit more from FOLFOX/XELOX than FOLFIRI as first-line chemotherapy (FOLFIRI: HR = 1.722, 95%CI: 1.026 ∼ 2.892, P = 0.040, compared with FOLFOX/XELOX). In contrast, patients with 0 or 1 above-mentioned genotype would have better outcomes if receiving FOLFIRI (FOLFIRI: HR = 0.422, 95%CI: 0.205 ∼ 0.870, P = 0.019, compared with FOLFOX/XELOX). Conclusions SNPs detection may play a predictive role in selecting first-line chemotherapy for advanced colorectal cancer patients. Radical resection of primary lesion is an independent factor for both PFS and OS. Disclosure All authors have declared no conflicts of interest.
Abeta(1-42) modulation of Akt phosphorylation via alpha7 nAChR and NMDA receptors.

Jonathan J. Abbott,D. Howlett,P. Francis,Robert J. Williams

IF: 5.133

Neurobiology of Aging

Abstract:Elevated Abeta and its deposition as senile plaques are pathogenic features of Alzheimer's disease. Abeta has been shown to be toxic to neurons and to inhibit long-term potentiation yet, the intracellular signalling pathways underlying these actions are unknown. We report for the first time that acute exposure of primary mouse neurons to 400nM Abeta(1-42) increased Akt phosphorylation in an alpha(7) nicotinic receptor and NMDA receptor dependant manner. However, prolonged incubation resulted in Akt phosphorylation returning to baseline consistent with the action of a physiological regulator. Analysis of an APP transgenic mouse (TAS10) revealed a significant deficit in hippocampal Akt phosphorylation at 13 months. This time point corresponds to the emergence of plaque formation and memory impairments in these mice. The present study suggests that Abeta(1-42) regulates Akt phosphorylation in a complex manner. Acutely, Abeta(1-42) stimulates Akt phosphorylation however, chronic exposure to Abeta in TAS10 mice resulted in a downregulation of Akt phosphorylation consistent with abnormalities in excitatory neurotransmission in these mice and with recent reports of Abeta(1-42) driven internalisation of NMDA receptors.
Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients

Lay Kek Teh,Sharina Hamzah,Hazwanie Hashim,Zakaria Bannur,Zainul Amiruddin Zakaria,Zakaria Hasbullani,John Kwong Siew Shia,Henry Fijeraid,Azmid Md Nor,Mohd Zailani,Prabu Ramasamy,Harris Ngow,Suneet Sood,Mohd Zaki Salleh

DOI: https://doi.org/10.1097/FTD.0b013e318290acd2

Abstract:Background: Dihydropyrimidine dehydrogenase (DPD) is a pyrimidine catabolic enzyme involved in the initial and rate-limiting step of the catabolic pathway of toxic metabolites of 5-fluorouracil (5-FU). Several studies have reported that deficiency of DPD and polymorphisms of its gene are related to 5-FU toxicities and death. Association between serum concentration of 5-FU and its related toxicity has also been previously demonstrated. Hence, this study aims to understand the role of DPYD variants in serum level of 5-FU and the risk of developing toxicity to prevent adverse reactions and maximize therapy outcome for personalized medicine. Methods: A total of 26 patients comprising 3 different ethnic groups (Malay, Chinese, and Indian) diagnosed with colorectal cancer and treated with 5-FU chemotherapy regimen from local hospital were recruited. Polymerase chain reaction and denaturing high-performance liquid chromatography methods were developed to screen polymorphisms of DPYD gene. High-performance liquid chromatography-based quantification assay was developed to measure the serum concentration of 5-FU among these patients. Results: Patients with DPYD genotypes of deficient enzyme activity had higher median serum levels of 5-FU compared with normal DPD group (median, 11.51 mcg/mL; 95% confidence interval, 10.18-16.11 versus median, 0.83 mcg/mL; 95% confidence interval, 0.55-5.90, Mann-Whitney U test; P = 0.010). Patients with neutropenia (n = 11) had significantly higher serum concentrations of 5-FU as compared with those with normal white blood cell count (n = 15) (Mann-Whitney U test, P = 0.031). Combined regression analysis showed that the predictive power of DPYD*5 (rs1801159) and 1896 T>C (rs17376848) for serum concentrations of 5-FU in the studied group was 36.6% (P = 0.04). Similarly, DPYD*5 and 1896 T>C accounted for 29.9% of the occurrences of neutropenia (analysis of variance, P = 0.017). Conclusions: This study revealed that DPYD*5 (rs1801159) and 1896 T>C (rs17376848) are potentially useful predictive markers of patients' responses to 5-FU chemotherapy. Pharmacogenotyping is therefore recommended to guide dosing of 5-FU and prevent neutropenia.
Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy

Ayman Madi,David Fisher,Timothy S Maughan,James P Colley,Angela M Meade,Julie Maynard,Vikki Humphreys,Harpreet Wasan,Richard A Adams,Shelley Idziaszczyk,Rebecca Harris,Richard S Kaplan,Jeremy P Cheadle

DOI: https://doi.org/10.1016/j.ejca.2018.07.009

Abstract:Background: Inherited genetic variants may influence response to, and side-effects from, chemotherapy. We sought to generate a comprehensive inherited pharmacogenetic profile for oxaliplatin and 5FU/capecitabine therapy in advanced colorectal cancer (aCRC). Methods: We analysed more than 200 potentially functional, common, inherited variants in genes within the 5FU, capecitabine, oxaliplatin and DNA repair pathways, together with four rare dihydropyrimidine dehydrogenase (DPYD) variants, in 2183 aCRC patients treated with oxaliplatin-fluoropyrimidine chemotherapy with, or without, cetuximab (from MRC COIN and COIN-B trials). Primary end-points were response, any toxicity and peripheral neuropathy. We had >85% power to detect odds ratios (ORs) = 1.3 for variants with minor allele frequencies >20%. Results: Variants in DNA repair genes (Asn279Ser in EXO1 and Arg399Gln in XRCC1) were most associated with response (OR 1.9, 95% confidence interval [CI] 1.2-2.9, P = 0.004, and OR 0.7, 95% CI 0.5-0.9, P = 0.003, respectively). Common variants in DPYD (Cys29Arg and Val732Ile) were most associated with toxicity (OR 0.8, 95% CI 0.7-1.0, P = 0.008, and OR 1.6, 95% CI 1.1-2.1, P = 0.006, respectively). Two rare DPYD variants were associated with increased toxicity (Asp949Val with neutropenia, nausea and vomiting, diarrhoea and infection; IVS14+1G>A with lethargy, diarrhoea, stomatitis, hand-foot syndrome and infection; all ORs > 3). Asp317His in DCLRE1A was most associated with peripheral neuropathy (OR 1.3, 95% CI 1.1-1.6, P = 0.003). No common variant associations remained significant after Bonferroni correction. Conclusions: DNA repair genes may play a significant role in the pharmacogenetics of aCRC. Our data suggest that both common and rare DPYD variants may be associated with toxicity to fluoropyrimidine-based chemotherapy.
DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan

Felicia Stefania Falvella,Stefania Cheli,Antonia Martinetti,Cristina Mazzali,Roberto Iacovelli,Claudia Maggi,Manuela Gariboldi,Marco Alessandro Pierotti,Maria Di Bartolomeo,Elisa Sottotetti,Roberta Mennitto,Ilaria Bossi,Filippo de Braud,Emilio Clementi,Filippo Pietrantonio

DOI: https://doi.org/10.1111/bcp.12631

Abstract:Aims: Triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan is a standard therapy for metastatic colorectal cancer (CRC). Single nucleotide polymorphisms (SNPs) in DPYD and UGT1A1 influence fluoropyrimdines and irinotecan adverse events (AEs). Low frequency DPYD variants (c.1905 + 1G > A, c.1679 T > G, c.2846A > T) are validated but more frequent ones (c.496A > G, c.1129-5923C > G and c.1896 T > C) are not. rs895819 T > C polymorphism in hsa-mir-27a is associated with reduced DPD activity. In this study, we evaluated the clinical usefulness of a pharmacogenetic panel for patients receiving triplet combinations. Methods: Germline DNA was available from 64 CRC patients enrolled between 2008 and 2013 in two phase II trials of capecitabine, oxaliplatin and irinotecan plus bevacizumab or cetuximab. SNPs were determined by Real-Time PCR. We evaluated the functional variants in DPYD (rare: c.1905 + 1G > A, c.1679 T > G, c.2846A > T; most common: c.496A > G, c.1129-5923C > G, c.1896 T > C), hsa-mir-27a (rs895819) and UGT1A1 (*28) genes to assess their association with grade 3-4 AEs. Results: None of the patients carried rare DPYD variants. We found DPYD c.496A > G, c.1129-5923C > G, c.1896 T > C in heterozygosity in 19%, 5% and 8%, respectively, homozygous rs895819 in hsa-mir-27a in 9% and homozygous UGT1A1*28 in 8%. Grade 3-4 AEs were observed in 36% patients and were associated with DPYD c.496A > G (odds ratio (OR) 4.93, 95% CI 1.29, 18.87; P = 0.021) and homozygous rs895819 in hsa-mir-27a (OR 11.11, 95% CI 1.21, 102.09; P = 0.020). Carriers of DPYD c.1896 T > C and homozygous UGT1A1*28 showed an OR of 8.42 (95% CI 0.88, 80.56; P = 0.052). Multivariate analysis confirmed an independent value for DPYD c.496A > G and c.1896 T > C. Conclusions: Concomitant assessment of DPYD variants and the UGT1A1*28 allele is a promising strategy needing further validation for dose personalization.
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant

Vincenzo De Falco,Maria Iole Natalicchio,Stefania Napolitano,Nicola Coppola,Giovanni Conzo,Erika Martinelli,Nicoletta Zanaletti,Pasquale Vitale,Emilio Francesco Giunta,Maria Teresa Vietri,Pietro Paolo Vitiello,Davide Ciardiello,Anna Marinaccio,Ferdinando De Vita,Fortunato Ciardiello,Teresa Troiani

DOI: https://doi.org/10.1097/MD.0000000000015759

Abstract:Introduction: Fluoropyrimidines such as 5-fluorouracil (5-FU) and its orally active prodrug, capecitabine, are widely used in the treatment of gastrointestinal cancer, including colorectal cancer. Dihydropyrimidine dehydrogenase (DPD) plays an important role in the 5-FU metabolism. Dihydropyrimidine dehydrogenase gene (DPYD) is a highly polymorphic gene with several hundreds of reported genetic variants and DPD activity levels vary considerably among individuals, with different 5-FU-related efficacy and toxicity. About 5% of the population is deficient in DPD enzyme activity. The most well studied DPYD variant is the IVS14+1G>A, also known as DPYD *2A. In this report, we present a case of a patient with a double heterozygote DPYD variant (DPYD activity score: 0,5 according to Clinical Pharmacogenetics Implementation Consortium) who experienced a severe fluoropyrimidine-related toxicity resolved without any consequence. Patient concerns: A 46-years-old Caucasian man with diagnosis of left colon adenocarcinoma underwent left hemicolectomy on July 2017: pT3 G3 N1c M0. According to the disease stage, he started an adjuvant therapy with XELOX using capecitabine at 50% of total dose, because of his DPYD IVS14+1G>A variant, detected before the treatment. Diagnosis: After few days, despite of this dose reduction, he experienced life-threatening adverse events such as mucositis G3, diarrhea G3, neutropenia G4, thrombocytopenia G4, and hyperbilirubinemia G3 according to Common Terminology Criteria for Adverse Events v 5.0. Interventions: As first, we set up an intensive rehydration therapy, antibiotic and antifungal prophylaxis, Granulocyte-Colony Stimulating Factors, and supportive blood transfusions. Additional genetic tests revealed a double heterozygote variant of DPYD gene (DPYD IVS14+1G>A and 2846A>T) which is a very rare situation and only 3 cases are described in literature, all of them concluded with patient's death. Outcomes: After 3 weeks of intensive therapy, the patient was fully recovered. Furthermore, all the whole-body CT scans performed since discharge from the hospital until now, have confirmed no evidence of disease. Conclusions: Recent studies demonstrated that screening strategy for the most common DPYD variants allowed for avoiding toxicities and saving money. This report underlines the importance of genotyping DPYD before treatment and emphasizes the role of genotype-guided dose individualization.
Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients

Reza Negarandeh,Ebrahim Salehifar,Fatemeh Saghafi,Hossein Jalali,Ghasem Janbabaei,Mohammad Javad Abdhaghighi,Anahita Nosrati

DOI: https://doi.org/10.1186/s12885-020-06904-3

IF: 4.638

2020-06-16

BMC Cancer

Abstract:5-Fluorouracil (5-FU) and capecitabine are fluoropyrimidine derivatives that mainly metabolized with dihydropyrimidine dehydrogenase enzyme (DPD). The genetic polymorphism in the genes encoding this enzyme may result in a decrease or loss of enzyme activity which may lead to the accumulation of medicines, their metabolites and potential toxicity.

oncology
The Evaluation of Dihydropyrimidine Dehydrogenase Enzyme Level in the Serum of Colorectal Cancer Iraqi Males on Fluoropyrimidine-Based Chemotherapy (Capecitabine)

Muhtada A Challoob,Nawar S Mohammed

DOI: https://doi.org/10.7759/cureus.44534

2023-09-01

Cureus

Abstract:The cornerstone of systemic chemotherapy for colorectal cancer (CRC) revolves around fluoropyrimidines. This class encompasses 5-fluorouracil (5-FU), which is administered intravenously, along with its oral prodrug counterpart, capecitabine. Central to the metabolism of both 5-FU and capecitabine is the pivotal enzyme dihydropyrimidine dehydrogenase (DPD). Operating at the rate-limiting juncture, DPD assumes a critical role. Notably, a deficiency in DPD significantly elevates the risk quotient for encountering unfavorable outcomes linked to the administration of fluoropyrimidines. This study seeks to assess the significance of DPD enzyme levels in the serum of Iraqi colorectal cancer male patients undergoing fluoropyrimidine-based chemotherapy, specifically with capecitabine. It adopts a case-control design and comprises 80 male participants. Those males are divided into two distinct groups. Group 1 comprises 45 male patients diagnosed with CRC who have experienced relapse subsequent to undergoing chemotherapy based on fluoropyrimidine (capecitabine). Their ages span from 41 to 71 years, and they were treated at the Misan Health Directorate/Misan Center for Tumor Treatment. Group 2 encompasses 35 male patients diagnosed with CRC who underwent fluoropyrimidine-based chemotherapy (capecitabine) without encountering relapse. Their ages range from 40 to 57 years. All participants were provided with comprehensive information regarding the research, and data collection occurred through a structured questionnaire. Subsequent to capecitabine-based treatment, serum samples were collected from CRC patients (stage III). The findings from this research indicate a notable elevation in DPD enzyme activity. Furthermore, a significant reduction in enzyme activity was observed among patients who experienced relapse, in contrast to those who remained non-relapsed. The results indicate that individuals with an insufficiency in DPD are notably more vulnerable to experiencing severe and potentially life-threatening side effects upon exposure to the commonly utilized chemotherapy drug, 5-FU.
Fluoropyrimidine-Associated Toxicity in Two Gastrointestinal Cancer Patients: Potential Role of Common DPYD Polymorphisms

Felicia Stefania Falvella,Marco Luoni,Stefania Cheli,Sergio Fava,Massimiliano Cergnul

DOI: https://doi.org/10.1159/000477333

Chemotherapy

Abstract:While the majority of patients can be treated safely with fluoropyrimidine, some experience severe fluoropyrimidine-associated toxicity. The frequency and severity of these adverse events vary from patient to patient and are partially explained by genetic polymorphism into the dihydropyrimidine dehydrogenase (DPYD) gene. Carriers of the rare allelic variants DPYD*2A, DPYD*13, and DPYD D949V are more likely to experience severe adverse reactions during fluoropyrimidine-based therapy. However, these 3 genetic variants explain only a small percentage of the overall drug toxicity, and more frequent ones such as homozygous or compound heterozygous DPYD V732I can play a key role.
Cardiac vein myocardial revascularization. An experimental study and report of 3 clinical cases.

J. S. Benedict,T. Buhl,R. Henney

DOI: https://doi.org/10.1016/s0003-4975(10)64254-3

1975-11-01

Abstract:
DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients.

Hong Zhang,Youming Li,Hao Zhang,Xi Jin

DOI: https://doi.org/10.1007/bf02698048

2007-01-01

Medical Oncology

Abstract:Background Dihydropyrimidine dehydrogenase (DPYD) plays an important role in the metabolism of 5-FU, which can directly influence the pharmacokinetics and toxicity of 5-FU in patients undergoing chemotherapy. However, little is known of the relationship between DPYD gene polymorphism and metabolism and chemotherapeutic toxicity of 5-FU in gastric carcinoma and colon carcinoma. The present genotyping study demonstrated the relationship between DPYD gene polymorphism among 75 gastric carcinoma and colon carcinoma patients and its impact on 5-FU pharmacokinetic and side effect.
Deciphering the potential value of 5-fluorouracil metabolic enzymes in predicting prognosis and treatment response of colorectal cancer patients

Kinjal K Gajjar,Hemangini H Vora,Toral P Kobawala,Trupti I Trivedi,Nandita R Ghosh

DOI: https://doi.org/10.1177/1724600817748539

Abstract:Introduction: 5-flourouracil (5-FU) is one of the standard chemotherapeutic drugs used today in the treatment of colorectal cancer patients. Disruption of 5-FU metabolic pathway may contribute to altered effectiveness towards 5-FU-based therapy. Hence, the study of 5-FU metabolizing enzymes might have the potential efficacy to predict survival and response to treatment in colorectal cancer patients. Materials and methods: Immunohistochemical localization of 5-FU metabolic enzymes (TS, MTHFR, DPYD, and TP) was evaluated in 143 untreated patients with colorectal cancer; their prognostic and predictive values were also evaluated. Results: Immuno-positivity for TS, MTHFR, DPYD, and TP was observed in 77%, 75%, 88%, and 96% of colorectal cancer patients, respectively. Univariate survival analysis in total patients showed that low DPYD expression significantly predicted adverse overall survival ( P=0.042). Moreover, subgroup of colon cancer patients with low TS expression was associated with unfavorable prognosis. TP expression also emerged as a prognosticator in the subgroup of early and advanced stage patients. Additionally, when effect of co-expression of 5-FU metabolic enzymes was evaluated in total patients, low coexpression of all four proteins was predictive of poor overall survival than for individuals expressing high coexpression of these proteins ( P=0.045). In contrast, none of the 5-FU metabolic enzymes-either singly or on coexpression-emerged as a useful biomarker of potential therapeutic value when evaluated in the subgroup of patients treated with 5-FU alone or 5-FU plus oxaliplatin. Conclusion: The above findings suggest that coexpression of 5-FU metabolic enzymes possess significant prognostic value and could be useful biomarkers in colorectal cancer patients.
Clinical Implementation of Rare and Novel DPYD Variants for Personalizing Fluoropyrimidine Treatment: Challenges and Opportunities

Elena De Mattia,Noemi Milan,Yehuda G Assaraf,Giuseppe Toffoli,Erika Cecchin

DOI: https://doi.org/10.7150/ijbs.97686

2024-07-02

Abstract:Fluoropyrimidines (FLs) [5-Fluorouracil, Capecitabine] are used in the treatment of several solid tumors. Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme for FL detoxification, and its deficiency could lead to severe, life-threatening or fatal toxicity after FL administration. Testing with a pharmacogenetic panel of four deleterious variants in the dihydropyrimidine dehydrogenase gene (DPYD) (DPYD*2A, DPYD*13, c.2846A > T, c.1129-5923C > G) prior to FL treatment, is recommended by scientific consortia (e.g., CPIC, DPWG) and drug regulatory agencies (e.g., EMA). However, this panel identifies < 20% of patients at risk of severe FL-related toxicity. Cumulative recent evidence highlights the potential clinical value of rare (minor allele frequency < 1%) and novel DPYD genetic variants for identifying an additional fraction of DPD-deficient patients at increased risk of severe FL-related toxicity. In this review, we aimed to comprehensively describe the available evidence regarding the potential clinical predictive role of novel and rare DPYD variants as toxicity markers in FL-treated patients, and to discuss the challenges and opportunities in tailoring FL treatment based upon clinical application of such markers. Although we must overcome existing barriers to the clinical implementation, the available data support that comprehensive assessment of the DPYD sequence, including rare and novel genetic variants, may significantly enhance the pre-emptive identification of at-risk patients, compared to the current targeted approach.
Sexual dimorphism in the effect of sound stress on neutrophil function

Adrienne S. Brown,J. Levine,P. Green

DOI: https://doi.org/10.1016/j.jneuroim.2008.08.005

IF: 3.221

2008-12-15

Journal of Neuroimmunology

Abstract:
Intra‐amniotic instillation of surfactants for the prevention of neonatal respiratory distress syndrome following preterm delivery

N. Agarwal,S. Bathwal,A. Kriplani,A. Deorari,N. Bhatla

DOI: https://doi.org/10.1016/j.ijgo.2016.03.039

2016-11-01

Abstract:
Polymorphisms of Dihydropyrimidine Dehydrogenase Gene and Clinical Outcomes of Gastric Cancer Patients Treated with Fluorouracil-Based Adjuvant Chemotherapy in Chinese Population.

Zhang Xiao-ping,Bai Zhi-bin,Chen Bao-an,Feng Ji-feng,Yan Feng,Jiang Zhi,Zhong Yue-jiao,Wu Jian-zhong,Chen Lu,Lu Zu-hong,Tong Na,Zhang Zheng-dong,Xu Pei-pei,Peng Miao-xin,Zhang Wen-jing,Wang Shuai

DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.2012.05.004

2012-01-01

Abstract:Background Dihydropyrimidine dehydrogenase (DPD), a key enzyme involved in the catabolism of 5-fluorouracil (5-FU), is the attractive candidate for pharmacogenetic research on efficacies and toxicities of 5-FU. The aim of this study is to explore the association between polymorphisms of dihydropyrimidine dehydrogenase gene (DPYD) and clinical outcomes of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in the Chinese population.Methods Three hundred and sixty-two patients with gastric cancer in the Chinese population were treated with fluorouracil-based adjuvant chemotherapy. The single nucleotide polymorphic genotypes of DPYD were determined by matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF-MS) using DNA samples isolated from peripheral blood collected before treatment.Results The average response rate for chemotherapy was 46.7%. A significantly different distribution of the rs1801159 (chi(2)=8.76, P=0.012) genotypes was observed. Homozygous genotype rs1801159A/A was over-represented in responsive patients. Conversely, carriers of the rs1801159A/G genotype were prevalent in non-responsive patients. In the haplotype association analysis, there was significant difference in global haplotype distribution between the groups (chi(2)=3.96, P=0.0465).Conclusions These results suggest that polymorphisms of rs1801159 in DPYD may be used as valuable predictors of the response to fluorouracil-based chemotherapy for gastric cancer patients in the Chinese population. Well-designed, comprehensive, and prospective studies on determining these polymorphisms of DPYD as predictive markers for gastric cancer in response to fluorouracil-based therapies are warranted. Chin Med J 2012;125(5):741-746
Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre

David K Lau,Caroline Fong,Faten Arouri,Lillian Cortez,Hannah Katifi,Reyes Gonzalez-Exposito,Muhammad Bilal Razzaq,Su Li,Aislinn Macklin-Doherty,Monica Arenas Hernandez,Michael Hubank,Charlotte Fribbens,David Watkins,Sheela Rao,Ian Chau,David Cunningham,Naureen Starling

DOI: https://doi.org/10.1186/s12885-023-10857-8

IF: 4.638

2023-04-26

BMC Cancer

Abstract:Background: Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolism of fluoropyrimidines. Variations in the encoding DPYD gene are associated with severe fluoropyrimidine toxicity and up-front dose reductions are recommended. We conducted a retrospective study to evaluate the impact of implementing DPYD variant testing for patients with gastrointestinal cancers in routine clinical practice in a high volume cancer centre in London, United Kingdom. Methods: Patients receiving fluoropyrimidine chemotherapy for gastrointestinal cancer prior to, and following the implementation of DPYD testing were identified retrospectively. After November 2018, patients were tested for DPYD variants c.1905+1G>A (DPYD*2A), c.2846A>T (DPYD rs67376798), c.1679T>G (DPYD*13), c.1236G>A (DPYD rs56038477), c.1601G>A (DPYD*4) prior to commencing fluoropyrimidines alone or in combination with other cytotoxics and/or radiotherapy. Patients with a DPYD heterozygous variant received an initial dose reduction of 25-50%. Toxicity by CTCAE v4.03 criteria was compared between DPYD heterozygous variant and wild type carriers. Results: Between 1st December 2018 and 31st July 2019, 370 patients who were fluoropyrimidine naïve underwent a DPYD genotyping test prior to receiving a capecitabine (n = 236, 63.8%) or 5FU (n = 134, 36.2%) containing chemotherapy regimen. 33 patients (8.8%) were heterozygous DPYD variant carriers and 337 (91.2%) were wild type. The most prevalent variants were c.1601G > A (n = 16) and c.1236G > A (n = 9). Mean relative dose intensity for the first dose was 54.2% (range 37.5-75%) for DPYD heterozygous carriers and 93.2% (42.9-100%) for DPYD wild type carriers. Overall grade 3 or worse toxicity was similar in DPYD variant carriers (4/33, 12.1%) as compared to wild-type carriers (89/337, 25.7%; P = 0.0924). Conclusions: Our study demonstrates successful routine DPYD mutation testing prior to the initiation of fluoropyrimidine chemotherapy with high uptake. In patients with DPYD heterozygous variants with pre-emptive dose reductions, high incidence of severe toxicity was not observed. Our data supports routine DPYD genotype testing prior to commencement of fluoropyrimidine chemotherapy.
DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU

Hong Zhang,You-Ming Li,Hao Zhang,Xi Jin

DOI: https://doi.org/10.1007/BF02698048

2007-01-01

Medical Oncology

Abstract:Background Dihydropyrimidine dehydrogenase (DPYD) plays an important role in the metabolism of 5-FU, which can directly influence the pharmacokinetics and toxicity of 5-FU in patients undergoing chemotherapy. However, little is known of the relationship between DPYD gene polymorphism and metabolism and chemotherapeutic toxicity of 5-FU in gastric carcinoma and colon carcinoma. The present genotyping study demonstrated the relationship between DPYD gene polymorphism among 75 gastric carcinoma and colon carcinoma patients and its impact on 5-FU pharmacokinetic and side effect. Methods We used a chemotherapy scheme based on 5-FU for the treatment of 75 patients with gastrointestinal carcinoma and detected the serum drug concentration and DPYD gene polymorphism (DPYD*2, *3, *4 *5 *9 *12). Results We found that there were no DPYD*2, *3, *4, *12 type mutation, in all patients. Of DPYD*9 gene polymorphism loci in 75 patients, 7 were heterozygote and 68 wild type; of DPYD*5 gene polymorphism loci in 75 patients, 11 were mutation and 23 heterozygote and 41 wild type. The elimination rate constant ( Ke ) value of DPYD*5 mutation group was statistically lower than the wild type (p=0.022). The incidence of middle-severe nausea and vomiting and white blood cell decreases in DPYD*5 gene type ranging from the highest to lowest can be listed as: mutation, heterozygote, wild type ( p<0.05 ). The incidence of middle-severe nausea and vomiting was significantly higher in DPYD*9 heterozygous genotype than in DPYD*9 wild genotype (p<0.05). Conclusions DPYD*5 gene mutation contribute to reduced DPYD enzyme activity and 5-FU dysmetabolism, which is associated with the accumulation of 5-FU and the chemotherapeutic toxicity in gastric carcinoma and colon carcinoma.
The association between DPYD gene polymorphism and chemotherapeutic toxicity of 5-FU in gastric carcinoma and colonic carcinoma]

Hong Zhang,You-ming Li,Chao-hui Yu,Sheng-qi Wang,Feng Ji,Chun-xiao Chen

DOI: https://doi.org/10.3760/j.issn:0578-1426.2007.02.006

2007-01-01

Abstract:To explore the relationship between dihydropyrimidine dehydrogenase (DPYD) gene polymorphism and metabolism as well as chemotherapeutic toxicity of 5-FU in gastric and colonic carcinoma.Chemotherapy scheme based on 5-FU was used for the treatment of 75 patients with gastrointestinal carcinoma. Serum drug concentration and DPYD gene polymorphism (DPYD*2, *3, *4, *5, *9, *12) were detected with high performance liquid chromatography (HPLC) and gene chip technique respectively.It was found that there was no DPYD*2, *3, *4, *12 type mutation in all the patients. Of the DPYD*9 gene polymorphism loci in the 75 patients, there were 7 with heterozygote (9.3%) and 68 with wide type (90.7%). Of the DPYD*5 gene polymorphism loci in the 75 patients, there were 11 with mutation (14.67%) and 23 heterozygote (30.67%) and 41 with wide type (54.67%). Ke value of DPYD*5 mutation was statistically lower than that of wild type (P=0.022). The incidence of middle-severe nausea and vomiting and white blood cell decrease in DPYD*5 gene type could be arranged from the highest to lowest as follows: mutation, heterozygote, wide type (P<0.05). The incidence of middle-severe nausea and vomiting was significantly higher in DPYD*9 heterozygous genotype than in DPYD*9 wild genotype (P<0.05).DPYD*5 gene mutation contributes to reduced DPYD enzyme activity and 5-FU dyes metabolism, which is associated with accumulation of 5-FU and chemotherapeutic toxicity in patients with gastric and colonic carcinoma.
A comparison of losses in small (<1 kW) drives using sine and space vector pulse width modulation schemes

C. Y. Leong,R. Grinberg,G. Makrides,Y. Wu,R. McMahon

DOI: https://doi.org/10.1109/PEDS.2005.1619856

2005-11-28

Abstract:This paper quantifies effects of using three different pulse width modulation (PWM) schemes on the losses in the inverter and induction motor of a 1 kW drive. Direct measurements of losses have been made with a calorimeter. Results show that for the inverter, discontinuous PWM excitation reduces losses by up to 15% compared to sine and symmetrical space vector PWM methods. However, at a low modulation index the greater harmonic content with discontinuous PWM increased motor losses by nearly 20%. This study demonstrates the importance of careful choice of modulation scheme to achieve high overall drive efficiency

[Cerebral ischemic vasculopathy: clinical and thermographic study in patients treated with papaveroline].

The Predictive Role of MTHFR and ABCG2 Single Nucleotide Polymorphisms on the Outcome of Advanced Colorectal Cancer Treated with First-Line Chemotherapy

Abeta(1-42) modulation of Akt phosphorylation via alpha7 nAChR and NMDA receptors.

Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients

Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy

DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan

A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant

Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients

The Evaluation of Dihydropyrimidine Dehydrogenase Enzyme Level in the Serum of Colorectal Cancer Iraqi Males on Fluoropyrimidine-Based Chemotherapy (Capecitabine)

Fluoropyrimidine-Associated Toxicity in Two Gastrointestinal Cancer Patients: Potential Role of Common DPYD Polymorphisms

Cardiac vein myocardial revascularization. An experimental study and report of 3 clinical cases.

DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients.

Deciphering the potential value of 5-fluorouracil metabolic enzymes in predicting prognosis and treatment response of colorectal cancer patients

Clinical Implementation of Rare and Novel DPYD Variants for Personalizing Fluoropyrimidine Treatment: Challenges and Opportunities

Sexual dimorphism in the effect of sound stress on neutrophil function

Intra‐amniotic instillation of surfactants for the prevention of neonatal respiratory distress syndrome following preterm delivery

Polymorphisms of Dihydropyrimidine Dehydrogenase Gene and Clinical Outcomes of Gastric Cancer Patients Treated with Fluorouracil-Based Adjuvant Chemotherapy in Chinese Population.

Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre

DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU

The association between DPYD gene polymorphism and chemotherapeutic toxicity of 5-FU in gastric carcinoma and colonic carcinoma]

A comparison of losses in small (&lt;1 kW) drives using sine and space vector pulse width modulation schemes

A comparison of losses in small (<1 kW) drives using sine and space vector pulse width modulation schemes